Shilpa Medicare Q3 FY26: consol PAT Rs 44.6 cr, revenue up 28% YoY
SHILPAMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.9 pts more than Nifty Microcap 250 and 1.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Shilpa Medicare Q3 FY26: consolidated revenue Rs 410.5 cr, up 28% YoY; PAT Rs 44.6 cr versus Rs 31.8 cr YoY. Standalone Q3 revenue Rs 177 cr, PAT Rs 15.9 cr. Exceptional loss of Rs 22 cr standalone and Rs 128.6 cr consolidated from new Labour Code gratuity impact and subsidiary impairments. Prior periods restated for INM Technologies merger. 1:1 bonus shares issued October 2025. Unmodified auditor review.
Strong consolidated earnings growth aided by absence of prior year one-time charge; muted standalone shows mixed picture with restated comparables.